Showing 771-780 of 1110 results for "".
- Johnson & Johnson Vision Announces New Data and Sustainability Activities at ESCRShttps://modernod.com/news/johnson-johnson-vision-announces-new-data-and-sustainability-activities-at-escrs/2481095/Johnson & Johnson Vision will be presenting new data and participating in a series of events at the upcoming 40th European Society of Cataract and Refractive Surgeons (ESCRS) congress September 16-20, 2022. The congress, taking place at the Milano Convention Centre in Milan, Italy, will showc
- Johnson & Johnson Vision Launches Acuvue Oasys Max 1-Dayhttps://modernod.com/news/johnson-johnson-vision-launches-acuvue-oasys-max-1-day/2481083/Johnson & Johnson Vision Care announced the launch of its newest innovation, Acuvue Oasys Max 1-Day contact lenses and Acuvue Oasys Max 1-Day Multifocal contact lenses for presbyopia. The lenses are designed with a combination of new technologies to help meet the needs of digit
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- Johnson & Johnson Vision Appoints Peter Menziuso as Company Group Chairmanhttps://modernod.com/news/johnson-johnson-vision-appoints-peter-menziuso-as-company-group-chairman/2480835/Johnson & Johnson Vision announced the appointment of Peter Menziuso as Company Group Chairman.
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv
- Johnson & Johnson Vision to Present New Data at AAO Demonstrating Benefits That New Innovations in Cataract Surgery Will Provide to Physicians and Patientshttps://modernod.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/Johnson & Johnson Vision will present a range of company-sponsored studies supporting new innovations in its cataract
- Johnson & Johnson Vision Presents Findings from New Myopia Research and Highlights Latest Contact Lens Innovations for Patients with Presbyopia at Academy 2021https://modernod.com/news/johnson-johnson-vision-presents-findings-from-new-myopia-research-and-highlights-latest-contact-lens-innovations-for-patients-with-presbyopia-at-academy-2021/2480391/Johnson & Johnson Vision announced that new myopia data outcomes will be presented at the upcoming 2021 American Academy of Optometry (AAO) annual
- Johnson & Johnson Vision Showcases New Veritas Vision System and Presents Latest Clinical Data at ESCRS 2021https://modernod.com/news/johnson-johnson-vision-showcases-new-veritas-vision-system-and-presents-latest-clinical-data-at-escrs-2021/2480324/Johnson & Johnson Vision will showcase the new Veritas Vision System and a range of clinical data relating
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti 1-Day Lenseshttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-1-day-lenses/2479496/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifical